Neovacs (ALNEV)

Business description

Neovacs is a French biotechnology company developing immunotherapy treatments using its proprietary kinoid platform. It has one product in Phase II for rheumatoid arthritis and Crohn?s disease and another in Phase I/II for lupus.

Termination of coverage

Update | Pharmaceutical & healthcare | 17/05/2017

Edison Investment Research is terminating coverage on Neovacs (ALNEV). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Edison's research is freely available. We will never ask for your credit card details and you do not need to register. By downloading this research you are agreeing to our terms and conditions, which you can read in full here.

Company news

Neovacs

Tue, 19 Jul 2016 12:00:00 GMT

Neovacs

Thu, 30 Mar 2017 16:24:23 GMT

Neovacs

Tue, 15 Dec 2015 07:15:23 GMT

Neovacs

Thu, 23 Jun 2016 15:11:15 GMT

Neovacs

Mon, 07 Mar 2016 07:20:02 GMT